A Novel β-lactam/β-lactamase Inhibitor: Ceftolozane/tazobactam
Ceftolozane/tazobactam is a novel generation cephalosporin and β-lactamase inhibitor combination antibiotic. It was approved for the treatment of adults (18 years and older) with complicated intraabdominal infections used in combination with metronidazole and complicated urinary tract infections by...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Turkish |
| Published: |
Galenos Yayinevi
2019-12-01
|
| Series: | Mediterranean Journal of Infection, Microbes and Antimicrobials |
| Subjects: | |
| Online Access: | http://mjima.org/text.php?&id=165 |
| _version_ | 1797910703317712896 |
|---|---|
| author | Kıvanç ŞEREFHANOĞLU |
| author_facet | Kıvanç ŞEREFHANOĞLU |
| author_sort | Kıvanç ŞEREFHANOĞLU |
| collection | DOAJ |
| description | Ceftolozane/tazobactam is a novel generation cephalosporin and β-lactamase inhibitor combination antibiotic. It was approved for the treatment of adults (18 years and older) with complicated intraabdominal infections used in combination with metronidazole and complicated urinary tract infections by the United States Food and Drug Administration. Its primary activity is against multidrug-resistant Pseudomonas aeruginosa and other aerobic Gram-negative bacteria. The main characteristic features of the antibiotic include: (1) a greater affinity for penicillin-binding proteins produced by P. aeruginosa; (2) better outer membrane permeability that displays resistance mechanisms against upregulation of efflux pumps, and (3) effectiveness against pathogens producing AmpC β-lactamases, primitive b-lactamases (TEM-1, TEM-2, SHV-1, and OXA-1), and extended spectrum β-lactamases. However, it is not effective against pathogens producing metallo-β-lactamases and Klebsiella pneumoniae carbapenemases. Ceftolozane/tazobactam is promising for difficult-to-treat infections caused by multidrug-resistant Gram-negative bacteria. Herein, the features of ceftolozane/tazobactam, including its pharmacokinetics, antimicrobial spectrum, and data from recent clinical studies are reviewed. |
| first_indexed | 2024-04-10T11:28:40Z |
| format | Article |
| id | doaj.art-5fb29bd7a9644f8eb16eb79da599b241 |
| institution | Directory Open Access Journal |
| issn | 2147-673X |
| language | Turkish |
| last_indexed | 2024-04-10T11:28:40Z |
| publishDate | 2019-12-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | Mediterranean Journal of Infection, Microbes and Antimicrobials |
| spelling | doaj.art-5fb29bd7a9644f8eb16eb79da599b2412023-02-15T16:18:12ZturGalenos YayineviMediterranean Journal of Infection, Microbes and Antimicrobials2147-673X2019-12-01810.4274/mjima.galenos.2019.2019.10A Novel β-lactam/β-lactamase Inhibitor: Ceftolozane/tazobactamKıvanç ŞEREFHANOĞLU0https://orcid.org/0000-0003-0585-8797İstanbul Yeni Yüzyıl University Faculty of Medicine, Gaziosmanpaşa Hospital, Department of Infectious Diseases and Clinical Microbiology, İstanbul, TurkeyCeftolozane/tazobactam is a novel generation cephalosporin and β-lactamase inhibitor combination antibiotic. It was approved for the treatment of adults (18 years and older) with complicated intraabdominal infections used in combination with metronidazole and complicated urinary tract infections by the United States Food and Drug Administration. Its primary activity is against multidrug-resistant Pseudomonas aeruginosa and other aerobic Gram-negative bacteria. The main characteristic features of the antibiotic include: (1) a greater affinity for penicillin-binding proteins produced by P. aeruginosa; (2) better outer membrane permeability that displays resistance mechanisms against upregulation of efflux pumps, and (3) effectiveness against pathogens producing AmpC β-lactamases, primitive b-lactamases (TEM-1, TEM-2, SHV-1, and OXA-1), and extended spectrum β-lactamases. However, it is not effective against pathogens producing metallo-β-lactamases and Klebsiella pneumoniae carbapenemases. Ceftolozane/tazobactam is promising for difficult-to-treat infections caused by multidrug-resistant Gram-negative bacteria. Herein, the features of ceftolozane/tazobactam, including its pharmacokinetics, antimicrobial spectrum, and data from recent clinical studies are reviewed.http://mjima.org/text.php?&id=165creesblhemodialysischronic kidney diseasecomplicated intra-abdominal infections |
| spellingShingle | Kıvanç ŞEREFHANOĞLU A Novel β-lactam/β-lactamase Inhibitor: Ceftolozane/tazobactam Mediterranean Journal of Infection, Microbes and Antimicrobials cre esbl hemodialysis chronic kidney disease complicated intra-abdominal infections |
| title | A Novel β-lactam/β-lactamase Inhibitor: Ceftolozane/tazobactam |
| title_full | A Novel β-lactam/β-lactamase Inhibitor: Ceftolozane/tazobactam |
| title_fullStr | A Novel β-lactam/β-lactamase Inhibitor: Ceftolozane/tazobactam |
| title_full_unstemmed | A Novel β-lactam/β-lactamase Inhibitor: Ceftolozane/tazobactam |
| title_short | A Novel β-lactam/β-lactamase Inhibitor: Ceftolozane/tazobactam |
| title_sort | novel β lactam β lactamase inhibitor ceftolozane tazobactam |
| topic | cre esbl hemodialysis chronic kidney disease complicated intra-abdominal infections |
| url | http://mjima.org/text.php?&id=165 |
| work_keys_str_mv | AT kıvancserefhanoglu anovelblactamblactamaseinhibitorceftolozanetazobactam AT kıvancserefhanoglu novelblactamblactamaseinhibitorceftolozanetazobactam |